IWO Meeting 17 November 2021 - Prof. Dr. Joop van den Bergh
- 1. Highlights ASBMR 2021 San Diego Copyright Prof. Dr. Joop van den Bergh
- 2. Highlights ASBMR 2021 San Diego X Copyright Prof. Dr. Joop van den Bergh
- 3. Copyright Prof. Dr. Joop van den Bergh
- 4. Relations that could be relevant for the meeting Company name Research funds Speaker board / consultancy Stakeholder Stock or other Amgen, UCB, Eli Lilly Amgen, UCB - - Disclosures Copyright Prof. Dr. Joop van den Bergh
- 5. Fracture risk Copyright Prof. Dr. Joop van den Bergh
- 6. Copyright Prof. Dr. Joop van den Bergh
- 7. Copyright Prof. Dr. Joop van den Bergh
- 8. Copyright Prof. Dr. Joop van den Bergh
- 9. Copyright Prof. Dr. Joop van den Bergh
- 10. Copyright Prof. Dr. Joop van den Bergh
- 11. Copyright Prof. Dr. Joop van den Bergh
- 12. Copyright Prof. Dr. Joop van den Bergh
- 13. Copyright Prof. Dr. Joop van den Bergh
- 14. Copyright Prof. Dr. Joop van den Bergh
- 15. Copyright Prof. Dr. Joop van den Bergh
- 16. Treatment - BMD Copyright Prof. Dr. Joop van den Bergh
- 17. Copyright Prof. Dr. Joop van den Bergh
- 18. Copyright Prof. Dr. Joop van den Bergh
- 19. Copyright Prof. Dr. Joop van den Bergh
- 20. Total Hip BMD Copyright Prof. Dr. Joop van den Bergh
- 21. Total Hip BMD Copyright Prof. Dr. Joop van den Bergh
- 22. Copyright Prof. Dr. Joop van den Bergh
- 23. Copyright Prof. Dr. Joop van den Bergh
- 24. Copyright Prof. Dr. Joop van den Bergh
- 25. Copyright Prof. Dr. Joop van den Bergh
- 26. Spine Total Hip Copyright Prof. Dr. Joop van den Bergh
- 27. Copyright Prof. Dr. Joop van den Bergh
- 28. Copyright Prof. Dr. Joop van den Bergh
- 29. Copyright Prof. Dr. Joop van den Bergh
- 30. Copyright Prof. Dr. Joop van den Bergh
- 31. Treatment drug holiday Copyright Prof. Dr. Joop van den Bergh
- 32. ASBMR/ECTS Clinical Debate: Intermittent Drug Holidays Are Mandatory for Long Term Bisphosphonate Treatment of Osteoporosis? ASBMR in support ECTS - against Copyright Prof. Dr. Joop van den Bergh
- 33. ASBMR/ECTS Clinical Debate: Intermittent Drug Holidays Are Mandatory for Long Term Bisphosphonate Treatment of Osteoporosis? ASBMR in support Winner: ECTS - against Copyright Prof. Dr. Joop van den Bergh
- 34. Copyright Prof. Dr. Joop van den Bergh
- 35. Copyright Prof. Dr. Joop van den Bergh
- 36. Mandatory = obligatory, binding Copyright Prof. Dr. Joop van den Bergh
- 37. Treatment: new and real-world data Copyright Prof. Dr. Joop van den Bergh
- 38. A Six-month Phase 2 Study of Oral PTH in Postmenopausal Women with Low Bone Mass 6 Month Bone Mineral Density (BMD) results Copyright Prof. Dr. Joop van den Bergh
- 39. Copyright Prof. Dr. Joop van den Bergh
- 40. Copyright Prof. Dr. Joop van den Bergh
- 41. Copyright Prof. Dr. Joop van den Bergh
- 42. Copyright Prof. Dr. Joop van den Bergh
- 43. Copyright Prof. Dr. Joop van den Bergh
- 44. Copyright Prof. Dr. Joop van den Bergh
- 45. Teriparatide / Abaloparatide Copyright Prof. Dr. Joop van den Bergh
- 46. Copyright Prof. Dr. Joop van den Bergh
- 47. Copyright Prof. Dr. Joop van den Bergh
- 48. Copyright Prof. Dr. Joop van den Bergh
- 49. Copyright Prof. Dr. Joop van den Bergh
- 50. Copyright Prof. Dr. Joop van den Bergh
- 51. Treatment safety Copyright Prof. Dr. Joop van den Bergh
- 52. ONJ Copyright Prof. Dr. Joop van den Bergh
- 53. Copyright Prof. Dr. Joop van den Bergh
- 54. Copyright Prof. Dr. Joop van den Bergh
- 55. Copyright Prof. Dr. Joop van den Bergh
- 56. AFF Copyright Prof. Dr. Joop van den Bergh
- 57. Copyright Prof. Dr. Joop van den Bergh
- 58. The cohort consists of 60 AFF patients (almost all treated with BPs) The AFF patients were classified into three groups: group 1, clinically suspected of a monogenic bone disorder and genetically confirmed with a pathogenic variant through NGS gene panel testing as routine medical care group 2, clinically suspected of a monogenic bone disorder without genetic confirmation group 3, no clinical suspicion of monogenic bone disorders Whole exome sequencing (WES) was performed in all patients and variants were classified based on the American College of Medical Genetics and Genomics (ACMG) classification guideline Copyright Prof. Dr. Joop van den Bergh
- 59. Copyright Prof. Dr. Joop van den Bergh
- 60. Copyright Prof. Dr. Joop van den Bergh
- 61. Copyright Prof. Dr. Joop van den Bergh
- 62. Copyright Prof. Dr. Joop van den Bergh
- 63. Copyright Prof. Dr. Joop van den Bergh
- 64. Copyright Prof. Dr. Joop van den Bergh
- 65. Copyright Prof. Dr. Joop van den Bergh
- 66. Copyright Prof. Dr. Joop van den Bergh
- 67. Copyright Prof. Dr. Joop van den Bergh
- 68. Copyright Prof. Dr. Joop van den Bergh
- 69. Vitamin D Copyright Prof. Dr. Joop van den Bergh
- 70. Copyright Prof. Dr. Joop van den Bergh
- 71. Copyright Prof. Dr. Joop van den Bergh
- 72. Copyright Prof. Dr. Joop van den Bergh
- 73. Copyright Prof. Dr. Joop van den Bergh
- 74. Copyright Prof. Dr. Joop van den Bergh
- 75. Copyright Prof. Dr. Joop van den Bergh
- 76. Copyright Prof. Dr. Joop van den Bergh
- 77. Copyright Prof. Dr. Joop van den Bergh
- 78. Copyright Prof. Dr. Joop van den Bergh
- 79. Copyright Prof. Dr. Joop van den Bergh
- 80. Copyright Prof. Dr. Joop van den Bergh
- 81. Copyright Prof. Dr. Joop van den Bergh
- 82. Artificial Intelligence Copyright Prof. Dr. Joop van den Bergh
- 83. Copyright Prof. Dr. Joop van den Bergh
- 84. Copyright Prof. Dr. Joop van den Bergh
- 85. Copyright Prof. Dr. Joop van den Bergh
- 86. Copyright Prof. Dr. Joop van den Bergh
- 87. Copyright Prof. Dr. Joop van den Bergh
- 88. Copyright Prof. Dr. Joop van den Bergh
- 89. Scoliosis and spine shape Copyright Prof. Dr. Joop van den Bergh
- 90. Copyright Prof. Dr. Joop van den Bergh
- 91. Copyright Prof. Dr. Joop van den Bergh